Organogenesis President and Chief Executive Officer Gary S. Gillheeney, Sr. Elected Chair of the Board of Directors

April 27, 2023

https://www.globenewswire.com/news-release/2023/04/27/2656213/0/en/Organogenesis-President-and-Chief-Executive-Officer-Gary-S-Gillheeney-Sr-Elected-Chair-of-the-Board-of-Directors.html

CANTON, Mass., April 27, 2023 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that its Board of Directors has elected President and Chief Executive Officer Gary S. Gillheeney, Sr., as Chair of the Board, effective immediately. Gillheeney will continue in his role as President and Chief Executive Officer, which he has held since 2014. Mr. Gillheeney succeeds Alan A. Ades, who has served as a director and as Chair of the Board since 2003. Mr. Ades will continue to serve as a director on the Company’s eleven-member Board of Directors.

Read more at globenewswire.com

Related news for (ORGO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.